Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimodivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 0.83 |
| ▸ | JAK2 | O60674 | 4/20 | 0.83 |
| ▸ | SRC | P12931 | 4/20 | 0.83 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.71 |
| ▸ | PRKACA | P17612 | 2/20 | 0.71 |
| ▸ | PLK1 | P53350 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimodivir SCHEMBL29351171 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL20150447 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL30321183 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL31554841 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728442 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL9941950 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL15723339 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL10304158 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728380 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL17771569 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | claimed |
| US-20180134730-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | BOROPHARM INC (US) | 2018-05-17 | — | — | US | claimed |
| WO-2016191079-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | BOROPHARM, INC. (US) | 2016-12-01 | — | — | WO | claimed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-11752214-B2 | Protein-antiviral compound conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20230233573-A1 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO (JP) | 2023-07-27 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230210860-A1 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION | SHIONOGI & CO (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2015038655-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150072982-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2015-03-12 | — | — | US | disclosed |
| US-8829007-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829007-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2442809-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | ENTPD5, NUDT15, ITPA | GSK3A 1520/4885GSK3B 1253/4885FLT3 421/4885 |
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | GSK3A 1477/4885GSK3B 1481/4885FLT3 2620/4885 |
| US-20230210860-A1 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION | NEU4, IDO1, CYP3A4 | GSK3A 3024/4885GSK3B 3372/4885FLT3 990/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | GSK3A 596/4885GSK3B 788/4885FLT3 471/4885 |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | GSK3A 301/4885GSK3B 272/4885FLT3 1519/4885 |
| US-20230233573-A1 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | PNPO, IDO1, PDXK | GSK3A 2551/4885GSK3B 2560/4885FLT3 649/4885 |
| US-20180134730-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | AZI2, BCCIP, ADAR | GSK3A 2267/4885GSK3B 2228/4885FLT3 3211/4885 |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | GSK3A 1026/4885GSK3B 1005/4885FLT3 1071/4885 |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | ENTPD5, NUDT1, ITPA | GSK3A 1413/4885GSK3B 1185/4885FLT3 465/4885 |
| US-11752214-B2 | Protein-antiviral compound conjugates | BMX, SARS1, VSIG8 | GSK3A 1374/4885GSK3B 1768/4885FLT3 1029/4885 |
| US-20150072982-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | GSK3A 1475/4885GSK3B 1479/4885FLT3 2630/4885 |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | GSK3A 1026/4885GSK3B 1005/4885FLT3 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.